Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07311746) titled 'Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia' on Dec. 29, 2025.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: M.D. Anderson Cancer Center
Condition:
T-cell Prolymphocytic Leukemia
Refractory T-Cell Prolymphocytic Leukemia
Intervention:
Drug: Ruxolitinib
Drug: Cladribine
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: June 1, 2026
Target Sample Size: 36
Countries ...